[{"id":"7b20d6d4-1189-47d1-bd64-55eb31d095f7","acronym":"HAP2HCT","url":"https://clinicaltrials.gov/study/NCT03849651","created_at":"2021-01-18T19:00:01.850Z","updated_at":"2024-07-02T16:35:22.870Z","phase":"Phase 2","brief_title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT03849651 - HAP2HCT","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10","pipe":" | ","alterations":" FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion","tags":["FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/31/2019","start_date":" 01/31/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-01-19"},{"id":"88795d74-ce07-42db-a37b-e34d26891eff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04809181","created_at":"2021-03-22T11:52:14.081Z","updated_at":"2024-07-02T16:35:55.126Z","phase":"Phase 2","brief_title":"Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients","source_id_and_acronym":"NCT04809181","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" WT1","pipe":" | ","alterations":" WT1 mutation","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 03/19/2021","start_date":" 03/19/2021","primary_txt":" Primary completion: 03/19/2024","primary_completion_date":" 03/19/2024","study_txt":" Completion: 03/19/2026","study_completion_date":" 03/19/2026","last_update_posted":"2023-02-21"},{"id":"eaf197f2-ef54-4e3d-bf47-4846ea78d6b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01314391","created_at":"2021-01-21T15:52:30.628Z","updated_at":"2024-07-02T16:37:32.084Z","phase":"","brief_title":"Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor","source_id_and_acronym":"NCT01314391","lead_sponsor":"Children's Oncology Group","biomarkers":" WT1","pipe":" | ","alterations":" WT1 mutation","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2016-05-18"}]